E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
ICU patients with ventilator-associated pneumonia |
|
E.1.1.1 | Medical condition in easily understood language |
patients who develop a pneumonia when receiving mechanical ventilation |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Does addition of inhalation tobramycin to standard IV treatment result in a higher clinical cure rate than standard IV antibiotic treatment alone in patients with ventilator-associated pneumonia. The initial response to treatment will be evaluated after 3 days of antimicrobial treatment.
|
|
E.2.2 | Secondary objectives of the trial |
Does addition of inhalation tobramycin to standard IV treatment result in a lower mortality and shorter length of stay than standard IV antibiotic treatment alone in patients with ventilator-associated pneumonia.
Does addition of inhalation tobramycin to standard IV treatment result in an improved bacterial eradication rate than standard IV antibiotic treatment alone in patients with ventilator-associated pneumonia.
In case of non-response at day 4, what are the causes of non-response?
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
The clinical suspicion of pneumonia is based on the ATS criteria: - new or progressive radiologic pulmonary infiltrate Together with at least two of the following three criteria: - temperature >38°C - leukocytosis >12,000/mm3 or leucopenia <4,000/mm3 - purulent respiratory secretions
|
|
E.4 | Principal exclusion criteria |
patients with allergy to tobramycin; pregnancy; expected to die within 72 hours after enrollment
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Nonresponse is considered when at least one of the following criteria is present: (1) No improvement of the arterial O2 tension to inspired O2 fraction ratio (2) Persistence of fever (≥38°C) or hypothermia (<35.5°C) together with purulent respiratory secretions (3) increase in the pulmonary infiltrates on chest radiograph of greater than or equal to 50% (4) occurrence of septic shock or multiple organ dysfunction syndrome, defined as three or more organ system failures not present on Day 1
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The initial response to treatment will be evaluated after 3 days of antimicrobial treatment. |
|
E.5.2 | Secondary end point(s) |
- 30-day and 90- day mortality rate - ICU survival - Number of days without mechanical ventilation - length of stay - discharge from the ICU - duration of mechanical ventilation - adverse events - day of normalisation of CRP, procalcitonin (PCT) and chest X-ray - eradication of pathogens (especially pseudomonas) - Clinical Pulmonary Infectious Score (31); APACHE II score; multiple organ dysfunction score (MODS) - Cytokine response - Causes of nonresponse. In patients with initial nonresponse to treatment, cultures of respiratory samples and blood will be obtained again, and the empiric antimicrobial treatment will be revised
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The initial response to treatment will be evaluated after 3 days of antimicrobial treatment. and at day 8, 14, discharge ICU, discharge hospital, Day 30, Day 90 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 2 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |